• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

South African approval of 4-in-1 combination ARV treatment for children a global first

Easy-to-administer treatment is an important step forward in the availability of optimal treatment options for infants and children living with HIV

14 Jun 2022

Viewpoint by
Dr Irene Mukui, Head of Disease, HIV, DNDi
Carol Ruffell, Director, DNDi GARDP Southern Africa 

We are excited to announce that the South African Health Products Regulatory Authority has approved a 4-in-1 fixed-dose combination treatment for children living with HIV, developed by DNDi and Cipla Limited.  

The 4-in-1 is a sweet-tasting combination of the four antiretrovirals (ARVs) abacavir, lamivudine, lopinavir, and ritonavir. The active ingredients are contained in strawberry-flavoured granules that can be sprinkled on breast milk, formula, or other age-appropriate foods. This makes the 4-in-1 a significant improvement over the lopinavir/ritonavir syrup that is bitter-tasting, has to be administered together with other separate formulations, and requires refrigeration. We expect the 4-in-1 to also be useful for children who have difficulties swallowing the tablet or pellet formulations.  

We celebrate South Africa’s leading role as the first country globally to grant the 4-in-1 regulatory approval. Interventions to prevent mother-to-child transmission have significantly reduced the number of children living with HIV in South Africa but approximately 2% of babies born to mothers living with the disease will contract it in utero, during birth, or in their first year of life. Around 238,000 children below the age of 15 in South Africa are living with HIV. Just over half are on treatment.  

The approval of the 4-in-1 represents an important step forward in the availability of optimal treatment options for infants and children living with HIV. It is our hope that similar approvals will be seen in other countries that have a high burden of disease among children.   

Although there has been significant improvement in the availability of newer and better drugs for children living with HIV in recent years, drug development for children typically lags far behind the development of drugs for adults, largely due to the challenges of conducting clinical trials that include children. Clinical trials including infants and young children conducted by DNDi and partners in Uganda concluded that the 4-in-1 is effective, easy for caregivers to administer, and adapted to use in resource-constrained settings as it does not require refrigeration and has a 24-month shelf-life. It is suitable for infants and children weighing between 3 and 25kg.  

We would like to take this opportunity to thank our pharmaceutical partner, Cipla, for its dedication to the development of this treatment and to obtaining regulatory approval for its use. We would also like to thank our funders, particularly Unitaid and the French Development Agency, our research partners, and the investigators, doctors, nurses, caregivers, and children who enabled the achievement of this important milestone. It is a breakthrough for paediatric research in African countries. 

As we celebrate this achievement, DNDi is actively preparing to facilitate access to the 4-in-1, which will complement other child-friendly HIV treatment options that have been introduced recently, including paediatric dolutegravir-based regimens. 

 


More information

Press release, 14 June 2022: Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa

Children Paediatric HIV

Read, watch, share

Loading...
Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License